Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
Herve Hoppenot
CEOHerve Hoppenot
Employees
2,524
Employees2,524
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,524
Employees2,524

INCY Key Statistics

Market cap
13.69B
Market cap13.69B
Price-Earnings ratio
503.19
Price-Earnings ratio503.19
Dividend yield
Dividend yield
Average volume
3.19M
Average volume3.19M
High today
High today
Low today
Low today
Open price
$70.66
Open price$70.66
Volume
0.00
Volume0.00
52 Week high
$83.95
52 Week high$83.95
52 Week low
$50.35
52 Week low$50.35

INCY News

TipRanks 2d
Incyte trading resumes

13:40 EST Incyte (INCY) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>...

TipRanks 2d
Merck ‘linked’ to takeover bid for Incyte, Sky News says

Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck (MRK), the US-listed pharma group, is the latest indu...

Benzinga 2d
What's Going On With Incyte Shares Tuesday?

Incyte Corporation INCY stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development. Th...

What's Going On With Incyte Shares Tuesday?

Analyst ratings

50%

of 28 ratings
Buy
46.4%
Hold
50%
Sell
3.6%

More INCY News

Benzinga 2d
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

On Monday, Incyte Corporation INCY announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria...

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
TipRanks 2d
Incyte price target lowered to $86 from $90 at BofA

BofA lowered the firm’s price target on Incyte (INCY) to $86 from $90 and keeps a Buy rating on the shares after the company announced they are pausing enrollme...

TipRanks 3d
Closing Bell Movers: Super Micro up 28% on compliance update

Check out this evening’s top movers from around Wall Street, compiled by The Fly. Don't Miss our Black Friday Offers: Discover the latest stocks recommended by...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.